US20060069283A1 - New process - Google Patents

New process Download PDF

Info

Publication number
US20060069283A1
US20060069283A1 US11/282,247 US28224705A US2006069283A1 US 20060069283 A1 US20060069283 A1 US 20060069283A1 US 28224705 A US28224705 A US 28224705A US 2006069283 A1 US2006069283 A1 US 2006069283A1
Authority
US
United States
Prior art keywords
group
ethoxy
phenyl
solution
preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/282,247
Inventor
Kjell Andersson
Alan Fischer
Panagiotis Ioannidis
Magnus Larsson
Maria Larsson
Sivaprasad Sivadasan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to US11/282,247 priority Critical patent/US20060069283A1/en
Publication of US20060069283A1 publication Critical patent/US20060069283A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734Ethers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/377Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/41Preparation of salts of carboxylic acids
    • C07C51/412Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Definitions

  • the present invention relates to novel resolution methods, which are useful in the D preparation of enantiomerically enriched intermediates which in their turn are useful in the preparation of compounds with a pharmacological effect on the insulin resistance syndrome (IRS).
  • IFS insulin resistance syndrome
  • Enantiomers can be produced using various techniques e.g. classical resolution by crystallisation of diastereomeric salts of the racemate, enzymatic resolution, chromatographic separation of the enantiomers separation of the racemate by chiral chromatography as well as by different enantioselective synthetic techniques.
  • the present invention relates to a process for the preparation of the (S)-enantiomer of a compound of the general formula I, comprising creating a racemic compound according to the general formula II with a chiral amine, thereby forming a diastereomeric salt according to the general formula III, subsequently separating the diastereomers by crystallisation followed by removal of the amine and thereafter, if suitable or necessary, deprotecting the compound so obtained with a deprotecting agent.
  • a free carboxylic acid function may in the end be protected with the group R p .
  • the present invention further relates to a process for the preparation of the (S)-enantiomer of a compound of the general formula V, comprising reacting a racemic compound according to the general formula II with a chiral compound, thereby forming a diastereomeric mixture according to general formula IV, subsequently separating the diastereomers by chromatography and/or crystallisation, thereafter treating the resulting (S-enantiomer of compound IV with a suitable reagent, e.g. an acid or base for removing the chiral auxiliary group, and thereafter, if desirable or necessary, deprotecting the resulting compound so obtained with a deprotecting agent.
  • a suitable reagent e.g. an acid or base for removing the chiral auxiliary group
  • a free carboxylic acid function may in the end be protected with the group R p .
  • the present invention further relates to a process for the preparation of the (S)-enantiomer of a compound of the general formula VII, comprising separating the enantiomers of a compound of the general formula VII by chiral chromatography and thereafter, if necessary, deprotecting the compound so obtained with a deprotecting agent.
  • the present invention further relates to a process for the preparation of a compound of the general formula VIII, comprising reducing a compound according to the general formula VI by for example hydrogenation in the presence of a suitable catalyst.
  • Compound VIII can then be further processed as described above for compounds according to general formula I or V.
  • Another aspect of the invention is a compound of the general formula VI wherein Q is a protecting group or H, and A is OH, a chiral auxiliary group or the group OR p , wherein R p is a protecting group and one or more of the hydrogen atoms of the phenyl group may be substituted by the equivalent number of halogen atoms.
  • the present invention further relates to a process for the preparation of the S-enantiomer of a compound of the general formula V, wherein A is OH, a chiral auxiliary group or the group OR p , wherein R p is a protecting group, and one or more of the hydrogen atoms of the phenyl group are optionally substituted by the equivalent number of halogen atoms, comprising reacting a racemic compound according to the general formula II wherein Q is a protecting group or H, and one or more of the hydrogen atoms of the phenyl group are optionally substituted by the equivalent number of halogen atoms, with a chiral compound, and where the carboxylic acid function of compound II may be activated before reaction with the chiral compound, thereby forming a diastereomeric mixture of general formula IV wherein Q is a protecting group or H, and R3 is a chiral auxiliary group, and one or more of the hydrogen atoms of the phenyl group are optionally substituted by
  • the present invention further relates to a process for the preparation of the (S)-enantiomer of a compound of the general formula VII, wherein Q is a protecting group or H, R2 is OH or the group OR p , wherein R p is a protecting group, and one or more of the hydrogen atoms of the phenyl group are optionally substituted by the equivalent number of halogen atoms, comprising separating the enantiomers by chiral chromatography and thereafter if desirable, deprotecting the Q group of the resulting compound with a deprotecting agent, and optionally protecting a free carboxylic acid function with the group R p .
  • the present invention further relates to a process for the preparation of a compound of the general formula VIII, wherein Q is a protecting group or H, A is OH, a chiral auxiliary group or the group OR p , wherein R p is a protecting group, and one or more of the hydrogen atoms of the phenyl group are optionally substituted by the equivalent number of halogen atoms, comprising reducing a compound according to the general formula VI wherein Q is a protecting group or H and A is OH, a chiral auxiliary group or the group OR p , wherein R p is a protecting group and one or more of the hydrogen atoms of the phenol group may be substituted by the equivalent number of halogen atoms, by for example hydrogenation in the presence of a suitable catalyst thereby forming a compound according to the general formula VIII.
  • Compound VIII can then be further processed as described above in connection with the preparation of a compound according to general formula I or V.
  • a in the general formulae VI and VIII is OR p wherein R p is a protecting group selected from the group consisting of H, benzyl or C 1-3 alkyl.
  • Q in the general formulae II-VIII is H or a protecting group selected from the group consisting of benzyl. acetyl and C 1-3 alkyl, preferably methyl.
  • one or more of the hydrogen atoms may be substituted by the equivalent number of halogen atoms, preferably chlorine or bromine or any combination thereof.
  • the deprotecting agent for Q when Q is C 1-3 alkyl is a thiol, preferably C 1-8 —SH, Ph—SH or salts thereof, or an acid. preferably hydrogen bromide or hydrogen iodide.
  • the deprotecting method for Q when Q is benzyl is hydrogenation in the presence of a suitable hydrogenation catalyst, preferably a palladium catalyst, preferably palladium on carbon.
  • Suitable chiral amines for use in the present invention include, without limitation, (S)-( ⁇ )-1-(1-naphthyl)-ethylamine, (S)-( ⁇ )-1-(1-phenyl)-ethylamine, quinine and analogues thereof, particularly quinidine, cinchonine or cinchonidine. (1R,2R)-( ⁇ )-pseudoephedrine or analogues thereof, (S)-phenyl glycinol, esters of chiral amino acids, aliphatic chiral amines or aromatic chiral amines.
  • the most preferred chiral amine is (5)-( ⁇ )-1-(1-naphthyl)-ethylamine.
  • the compound according to general formula II is reacted with a chiral compound to give a diastereomeric mixture according to general formula IV, the diastereomers afterwards separated by chromatography and/or crystallisation, where the chiral auxiliary group is suitably a chiral amine.
  • the chiral compound is suitably (2R)-2-amino-2-phenyl-1-ethanol or (2S)-2-amino-2-phenyl-1-ethanol.
  • the compound of the general formula III may be re-crystallized before the chiral amine is removed.
  • the compound according to general formula V is hydrolysed under acidic or basic conditions, which is suitably an inorganic acid and preferably a strong inorganic acid, such as HCl, HBr, Hl, H 2 SO, and/or HNO 3 .
  • the compound according to the general formula is reduced by for example hydrogenation in the presence of a suitable catalyst, preferably palladium on carbon.
  • the catalyst may be a chiral catalyst.
  • Group A in the general formula VI is OH, a chiral auxiliary group or the group OR p , wherein R p is a protecting group selected from the group consisting of H, benzyl or C 1-3 alkyl.
  • the chiral auxiliary group is suitably chosen from the group of terpenes and oxazolidinones.
  • an elevated temperature relates to a temperature in the range of from about 60° C. to about 180° C., suitably from 100° C. to 140° C.
  • enantiomerically enriched means a compound with an e.e. value of at least about 50%, suitably at least 80%, preferably at least 90% and more preferably at least 95%.
  • the overall yield of the subtitle compound was 58% of the theoretical value (loss was in evaporation).
  • the chemical purity was >99%.
  • the toluene layer was then evaporated to remove the remaining water.
  • methanesulfonic acid (2.11 g, 22 mmol, 0.03 eq).
  • the toluene solution was refluxed with a Dean-Starke device connected until full conversion was achieved.
  • the solution was cooled to 25° C.
  • the solution was then washed with sodium hydroxide (aq, 48%) (1.83 g, 22 mmol. 0.03 eq.) diluted in water (15 ml).
  • (2S)-2-ethoxy-3-(4-hydroxyphenyl) propanoic acid (874 g, 4.16 mol, 1.0 eq.) was dissolved in EtOAc (1250 ml). To this solution were charged ethanol (3000 ml) and HCl (37°, aq.) (40 ml, 0.48 mol, 0.12 eq.). The solution was heated to boiling (about 72° C.) and water/EtOAc/EtOH (2000 ml) was distilled off. Another portion of EtOH (2000 ml) was charged and another 2000 ml was distilled off. This procedure was repeated once more. At this point approximately 95% conversion was reached.
  • Ethyl 2,2-diethoxy ethanoate (47.5 kg, 263 mol) was treated for 20 h at 60° C. with iodine (0.1 kg) and acetylchloride (21.9 kg, 279 mol, addition time 2 h).
  • the resulting low boiling reaction by-products were distilled off at 40° C./170 mbar resulting in a dark-colored liquid (50 kg, GLC: 89% area, 100 % yield (content corrected).
  • the TPPO was filtered off again and the mother-liquor was concentrated until no more solvents distilled.
  • 2-Propanol (260 L) and seeding crystals (ethyl 3-[4-(benzyloxy)phenyl]-2-ethoxy-2-propenoate) (50 g) were added before cooling to 0° C.
  • the resulting suspension was filtered and the isolated material dried at 40° C./160 mbar.
  • the overall yield was 44.5 kg, 65% (GLC: 99% area).
  • Ethyl 3-[4-(benzyloxy)phenyl]-2-ethoxy-2-propenoate was converted to ethyl 3-[4-(benzyloxy)phenyl]-2-ethoxy-2-propanoate in two identically sized trials.
  • Ethyl 3-[4-(benzyloxy)phenyl]-2-ethoxy-2-propenoate (16 kg, 48.5 mol) was dissolved in EtOAc (80 L) and Pd/C 10% (0.79 kg) suspended in EtOAc (2.5 L) was added.
  • the vessel was inertised and filled-with H 2 .
  • the hydrogenation was initiated by starting the stirrer and lasted 26 hours.
  • the catalyst was filtered off (glass filter/Cellite (2.5 kg)).
  • (2S)-3 -[4-(benzyloxy)phenyl ]-2-ethoxy-N-[(1R)-2-hydroxy-1-phenylethyl]propanamide (4.3 kg, 10.2 mol) were dissolved in dioxane (30 L) and diluted with deionized water (35 L). To this opaque reaction mixture, H 2 SO 4 (19.2 kg, 192 mol) was added. The reaction temperature was raised to 80 ° C. and kept at 80 ° C. for 15 hours. The reaction mixture was extracted twice with TBME (64 L, 70 L) at room temperature. The combined organic phases were extracted twice with 1 M NaOH (2 ⁇ 20 L, 2 ⁇ 20 mol).
  • aqueous phases were acidified with H 2 SO 4 (24 L, 24 mol.), extracted with TBME (40 L) and the organic phases dried with saturated NaCl solution.
  • the solution was concentrated to yield 64 L concentrate which contained 2.9 kg, 100% (GLC 68% area (2S)-3-[4-(benzyloxy)phenyl]-2-ethoxypropanoic acid and 28% area (2S)-2-ethoxy-(4-hydroxyphenyl)propanoic acid).
  • the diastereomeric mixture (21.6 kg, 51.6 mol, (2)-3-[4-(benzyloxy)phenyl]-2-ethoxy-N-[(1S)-(2-hydroxy-1-phenylethyl]propanamide/(2R)-3 -[4-(benzyloxy)phenyl]-2-ethoxy-N-[(1S)-(2-hydroxy-1-phenylethyl]propanamide) was suspended in ethyl acetate (113 L) and heated to reflux for 30 min. The solution was slowly (1 h) cooled to 36-40° C. and heptane (113 L) was added under vigorous stirring over 2 h. The mixture was cooled to 15° C. over 4 h.
  • thionylchloride (1.85 L, 25.56 mol, 2 equiv.) was added over 30 min—gas was developed heavily.
  • the reaction mixture was slowly heated (jacket temperature: 65° C.). At 35° C. inner temperature the development of gas was so vigorous, that the washer was overburdened. The heating was stopped and the inner temperature was kept at 35° C. for 15 min. Then heating was continued and the reaction mixture was kept under reflux for 2h 30 min.

Abstract

The present invention relates to novel resolution methods, which are useful in the preparation of enantiomerically enriched intermediates which in their turn are useful in the prepartion of compounds with a pharmacological effect on the insulin resistance syndrome (IRS). It is such a process that the present inventions sets out to define, and more particularly for the preparation of the (S)-enantioner of certain 2-ethoxy-3-(4-hydroxyphenyl)propanoic acids and derivatives thereof.

Description

    FIELD OF INVENTION
  • The present invention relates to novel resolution methods, which are useful in the D preparation of enantiomerically enriched intermediates which in their turn are useful in the preparation of compounds with a pharmacological effect on the insulin resistance syndrome (IRS).
  • BACKGROUND OF INVENTION
  • Enantiomers can be produced using various techniques e.g. classical resolution by crystallisation of diastereomeric salts of the racemate, enzymatic resolution, chromatographic separation of the enantiomers separation of the racemate by chiral chromatography as well as by different enantioselective synthetic techniques.
  • There is, however, a need to select a suitable combination of process steps as well as suitable conditions of each individual step in order to achieve an enantiomeric purity, which is sufficient to provide a pharmaceutically and economically feasible process.
  • It is such a process that the present invention sets out to define, and more particularly for the preparation of the (S)-enantiomer of certain 2-ethoxy-3-(4-hydroxyphenyl) propanoic acids and derivatives thereof.
  • SUMMARY OF INVENTION
  • The present invention relates to a process for the preparation of the (S)-enantiomer of a compound of the general formula I, comprising creating a racemic compound according to the general formula II with a chiral amine, thereby forming a diastereomeric salt according to the general formula III, subsequently separating the diastereomers by crystallisation followed by removal of the amine and thereafter, if suitable or necessary, deprotecting the compound so obtained with a deprotecting agent. Optionally a free carboxylic acid function may in the end be protected with the group Rp.
  • The present invention further relates to a process for the preparation of the (S)-enantiomer of a compound of the general formula V, comprising reacting a racemic compound according to the general formula II with a chiral compound, thereby forming a diastereomeric mixture according to general formula IV, subsequently separating the diastereomers by chromatography and/or crystallisation, thereafter treating the resulting (S-enantiomer of compound IV with a suitable reagent, e.g. an acid or base for removing the chiral auxiliary group, and thereafter, if desirable or necessary, deprotecting the resulting compound so obtained with a deprotecting agent. Optionally a free carboxylic acid function may in the end be protected with the group Rp.
  • The present invention further relates to a process for the preparation of the (S)-enantiomer of a compound of the general formula VII, comprising separating the enantiomers of a compound of the general formula VII by chiral chromatography and thereafter, if necessary, deprotecting the compound so obtained with a deprotecting agent.
  • The present invention further relates to a process for the preparation of a compound of the general formula VIII, comprising reducing a compound according to the general formula VI by for example hydrogenation in the presence of a suitable catalyst. Compound VIII can then be further processed as described above for compounds according to general formula I or V.
  • Another aspect of the invention is a compound of the general formula VI
    Figure US20060069283A1-20060330-C00001

    wherein Q is a protecting group or H, and A is OH, a chiral auxiliary group or the group ORp, wherein Rp is a protecting group and one or more of the hydrogen atoms of the phenyl group may be substituted by the equivalent number of halogen atoms.
  • DETAILED DESCRIPTION OF INVENTION
  • More specifically, the present invention relates to a process for the preparation of the (S)-enantiomer of a compound of the general formula I,
    Figure US20060069283A1-20060330-C00002

    wherein R2 is OH or the group ORp, wherein Rp is a protecting group, and one or more of the hydrogen atoms of the phenyl group are optionally substituted by the equivalent number of halogen atoms, comprising reacting a racemic compound according to the general formula II
    Figure US20060069283A1-20060330-C00003

    wherein Q is a protecting group or H, and one or more of the hydrogen atoms of the phenyl group are optionally substituted by the equivalent number of halogen atoms, with a chiral amine, thereby forming a salt according to the general formula III
    Figure US20060069283A1-20060330-C00004

    wherein Q is a protecting group or H, and R1 is a chiral amine, and one or more of the hydrogen atoms of the phenyl group are optionally substituted by the equivalent number of halogen atoms, subsequently separating the diastereomers by crystallisation followed by removal of the amine, and thereafter, if desirable, deprotecting the Q group of the resulting compound with a deprotecting agent. Optionally a free carboxylic acid function may in the end be protected with the group Rp.
  • The present invention further relates to a process for the preparation of the S-enantiomer of a compound of the general formula V,
    Figure US20060069283A1-20060330-C00005

    wherein A is OH, a chiral auxiliary group or the group ORp, wherein Rp is a protecting group, and one or more of the hydrogen atoms of the phenyl group are optionally substituted by the equivalent number of halogen atoms, comprising
    reacting a racemic compound according to the general formula II
    Figure US20060069283A1-20060330-C00006

    wherein Q is a protecting group or H, and one or more of the hydrogen atoms of the phenyl group are optionally substituted by the equivalent number of halogen atoms, with a chiral compound, and where the carboxylic acid function of compound II may be activated before reaction with the chiral compound, thereby forming a diastereomeric mixture of general formula IV
    Figure US20060069283A1-20060330-C00007

    wherein Q is a protecting group or H, and R3 is a chiral auxiliary group, and one or more of the hydrogen atoms of the phenyl group are optionally substituted by the equivalent number of halogen atoms, subsequently separating the diastereomers by chromatography and/or crystallisation, thereafter, if desirable, removing the R3 group of the resulting (S)-enantiomer according to general formula IV with a suitable reagent, such as an acid or base, and, if desirable, deprotecting the Q group of the resulting (S)-enantiomer according to general formula IV with a deprotecting agent. Optionally a free carboxylic acid function may in the end be protected with the group Rp.
  • The present invention further relates to a process for the preparation of the (S)-enantiomer of a compound of the general formula VII,
    Figure US20060069283A1-20060330-C00008

    wherein Q is a protecting group or H, R2 is OH or the group ORp, wherein Rp is a protecting group, and one or more of the hydrogen atoms of the phenyl group are optionally substituted by the equivalent number of halogen atoms, comprising separating the enantiomers by chiral chromatography and thereafter if desirable, deprotecting the Q group of the resulting compound with a deprotecting agent, and optionally protecting a free carboxylic acid function with the group Rp.
  • The present invention further relates to a process for the preparation of a compound of the general formula VIII,
    Figure US20060069283A1-20060330-C00009

    wherein Q is a protecting group or H, A is OH, a chiral auxiliary group or the group ORp, wherein Rp is a protecting group, and one or more of the hydrogen atoms of the phenyl group are optionally substituted by the equivalent number of halogen atoms, comprising reducing a compound according to the general formula VI
    Figure US20060069283A1-20060330-C00010

    wherein Q is a protecting group or H and A is OH, a chiral auxiliary group or the group ORp, wherein Rp is a protecting group and one or more of the hydrogen atoms of the phenol group may be substituted by the equivalent number of halogen atoms, by for example hydrogenation in the presence of a suitable catalyst thereby forming a compound according to the general formula VIII. Compound VIII can then be further processed as described above in connection with the preparation of a compound according to general formula I or V.
  • In a preferred embodiment of the present invention, A in the general formulae VI and VIII is ORp wherein Rp is a protecting group selected from the group consisting of H, benzyl or C1-3 alkyl.
  • In another preferred embodiment of the present invention. Q in the general formulae II-VIII is H or a protecting group selected from the group consisting of benzyl. acetyl and C1-3 alkyl, preferably methyl.
  • The use of protecting groups generally is described in ‘Protective Groups in Organic Synthesis’, 2nd edition (1991), T. W. Greene & P. G. M. Wutz, Wiley-Interscience.
  • In the phenyl group of the general formulae I to VIII. one or more of the hydrogen atoms may be substituted by the equivalent number of halogen atoms, preferably chlorine or bromine or any combination thereof.
  • In further preferred embodiments, the deprotecting agent for Q when Q is C1-3 alkyl is a thiol, preferably C1-8—SH, Ph—SH or salts thereof, or an acid. preferably hydrogen bromide or hydrogen iodide.
  • In further preferred embodiments, the deprotecting method for Q when Q is benzyl is hydrogenation in the presence of a suitable hydrogenation catalyst, preferably a palladium catalyst, preferably palladium on carbon.
  • Suitable chiral amines for use in the present invention include, without limitation, (S)-(−)-1-(1-naphthyl)-ethylamine, (S)-(−)-1-(1-phenyl)-ethylamine, quinine and analogues thereof, particularly quinidine, cinchonine or cinchonidine. (1R,2R)-(−)-pseudoephedrine or analogues thereof, (S)-phenyl glycinol, esters of chiral amino acids, aliphatic chiral amines or aromatic chiral amines. The most preferred chiral amine is (5)-(−)-1-(1-naphthyl)-ethylamine.
  • In the present invention, the compound according to general formula II is reacted with a chiral compound to give a diastereomeric mixture according to general formula IV, the diastereomers afterwards separated by chromatography and/or crystallisation, where the chiral auxiliary group is suitably a chiral amine. The chiral compound is suitably (2R)-2-amino-2-phenyl-1-ethanol or (2S)-2-amino-2-phenyl-1-ethanol.
  • In the present invention, the compound of the general formula III may be re-crystallized before the chiral amine is removed.
  • In the present invention, the compound according to general formula V is hydrolysed under acidic or basic conditions, which is suitably an inorganic acid and preferably a strong inorganic acid, such as HCl, HBr, Hl, H2SO, and/or HNO3.
  • In the present invention, the compound according to the general formula is reduced by for example hydrogenation in the presence of a suitable catalyst, preferably palladium on carbon. The catalyst may be a chiral catalyst. Group A in the general formula VI is OH, a chiral auxiliary group or the group ORp, wherein Rp is a protecting group selected from the group consisting of H, benzyl or C1-3 alkyl. The chiral auxiliary group is suitably chosen from the group of terpenes and oxazolidinones.
  • When deprotection of the Q group is suitable or necessary, the compound with a deprotecting group is subsequently treated with a deprotecting agent, for C1-3 alkyl protecting groups suitably at an elevated temperature. In this context, “an elevated temperature” relates to a temperature in the range of from about 60° C. to about 180° C., suitably from 100° C. to 140° C.
  • The enantiomeric excess (e.e.) value is defined as e . e . = area of ( S ) -isomer - area  of ( R ) -isomer area of ( S ) -isomer + area  of ( R ) -isomer
  • In the present invention, enantiomerically enriched means a compound with an e.e. value of at least about 50%, suitably at least 80%, preferably at least 90% and more preferably at least 95%.
  • EXAMPLES
  • The following Examples are intended to illustrate, but in no way limit the scope of the invention.
  • Example 1 Ethyl (2g)-2-ethoxy-3-(4-hydroxyphenyl) propanoate
  • a) Preparation of ethyl 2-ethoxyethanoate
  • A solution of 2-chloroacetic acid (50 g, 529 mmol, 1.0 eq) in absolute ethanol(110 ml, 2.2 vol.) was charged to an ethanol solution of sodium ethoxide (494 ml, 21%, 90 g, 1.32 mol, 2.5 eq). The temperature during the charging was kept at 15-25° C. When the charging was completed the temperature was raised to 50° C. The reaction mixture was cooled to 15° C. when >95% conversion was achieved. HCl (g) was then charged until the pH of the mixture was<1. When the conversion was>95% the slurry was cooled to 15° C. and neutralized to pH 5-7 with sodium ethoxide solution (approximately 5-20% of the initially charged amount). After neutralisation the slurry was cooled to 5° C. and ethyl acetate (150. ml, 3 vol.) was charged. The sodium chloride formed in the reaction was then-filtered off and washed with ethyl acetate. The solution was then evaporated. Maximum remaining ethanol was 20%.
  • The overall yield of the subtitle compound was 58% of the theoretical value (loss was in evaporation). The chemical purity was >99%.
  • b) Preparation of ethyl 2-ethoxy-3-(4-methoxyphenyl) propenoate
  • 4-Methoxybensaldehyde (100 g, 734 mmol, 1.0 eq.) and ethyl 2-exthoxyethanoate (116 g, 881 mmol, 1.2 eq.) was dissolved in THF (600 ml, 6 vol.) under an atmosphere of nitrogen. The solution was cooled to −20° C. To the resulting solution, a solution of potassium tert-butoxide (98.8 g, 880 mmol. 1.2 eq) in THF (704 ml, 7.1 vol. corresponding to potassium tert-butoxide) was slowly charged while maintaining the temperature<−10° C. After the charging was completed, the reaction mixture was stirred for 1 hour at a temperature of −15° C. to −10° C. To the slurry, was then charged glacial acetic acid (53 g, 1.24 mol. 1.4 eq.) maintaining the temperature at<+5° C. The THF was then evaporated until about ⅓ remained. Toluene (824 ml, 8.24 vol.) was added and the rest of the THF evaporated. Water (200 ml, 2 vol.) and methanesulfonic acid (50 ml, 0.5 vol.) were added to the toluene slurry to give a pH in the water layer of 2-3. The water layer was separated off. The toluene layer was then evaporated to remove the remaining water. To the toluene solution was added methanesulfonic acid (2.11 g, 22 mmol, 0.03 eq). The toluene solution was refluxed with a Dean-Starke device connected until full conversion was achieved. The solution was cooled to 25° C. The solution was then washed with sodium hydroxide (aq, 48%) (1.83 g, 22 mmol. 0.03 eq.) diluted in water (15 ml).
  • The overall yield of the subtitle compound was approximately 52% of the theoretical value.
  • c) Preparation of 2-ethoxy-3-(4-methoxyphenyl) propenoic acid
  • NaOH (aq., 48%) (122 g, 1.46 mol, 2.0 eq.), water (244 ml. 2.44 vol.) and EtOH (90 ml, 0.9 vol.) were charged to the toluene solution of ethyl 2-ethoxy-3-(4-methoxyphenyl) propenoate (approximately 96 g, 382 mmol. 0.52 eq.). The reaction mixture was heated to 50° C. and stirred until full conversion was achieved. After the reaction was complete, the toluene layer was separated off and the water layer was then washed with toluene (100 ml, 1 vol.). After separation, the water layer was cooled to +5° C. and acidified with conc. HCl (approximately 173 ml, 2.1 mol. 2.9 eq.). The temperature was kept<10° C. during the charging of the acid. EtOAc (100 ml, 1 vol.) was added to the acidic water slurry. After extraction the phases were separated. The EtOAc solution was evaporated and toluene (288 ml, 3 vol.) was added. The toluene solution was seeded with 2-ethoxy-3-(4-methoxyphenyl) propenoic acid, and cooled to 0° C. After crystallisation the material was filtered. The wet substance was used without drying in the subsequent step.
  • The overall yield of the subtitle compound was 42% of the theoretical value for step b & c together. The chemical purity was 99.7%.
  • d) Preparation of 2-ethoxy-3-(4-methoxyphenyl) propanoic acid
  • Palladium on charcoal (5%, 60% water wet) (13.2 g, 0.26 g Pd, 2.44 mmol Pd. 0.0054 eq.) was charged to a solution of 2-ethoxy-3-(4-methoxyphenyl) propenoic acid (100 g, 450 mmol. 1.0 eq.) in ethanol (800 ml, 8 vol.) under a nitrogen atmosphere. The vessel was then pressurized with hydrogen to 4 bar total pressure. The hydrogenation was continued until full conversion was achieved. The catalyst was filtered off and the ethanol was evaporated under vacuum. Toluene (500 ml, 5 vol.) was added and then evaporated off. The residue was dissolved in toluene (500 ml, 5 vol.) and evaporated to a volume of 260 ml. The solution was heated to 50° C. and isooctane (800 ml, 8 vol.) was added. The solution was cooled to 35° C. and then seeded with 2-ethoxy-3-(4-methoxyphenyl) propanoic acid. The temperature was maintained at 35° C. for 30 min. The thin slurry was then cooled at a rate of 10° C./hour down to +5° C. which was maintained overnight. The crystals were then filtered off and washed with isooctane (220 ml, 2.2 vol.) The crystals were dried under vacuum at 30° C.
  • The yield of the subtitle compound was 88% of the theoretical value. The chemical purity was 99.8%.
  • e) Preparation of (1S)-1-(1-naphthyl)-1-ethanaminium (2S)-2-ethoxy-3-(4-methoxyphenyl) propanoate
  • A solution of 2-ethoxy-3-(4-methoxyphenyl) propionic acid (100 g, 446 mmol, 1.0 eq.) in i-PrOAc (2000 ml. 20 vol.) was stirred at 0-5° C. under a nitrogen atmosphere. (S)-(−)-1-(1-naphthyl) ethylamine (45.8 g, 268 mmol, 0.6 eq.) was added to the resulting solution. The resulting suspension was heated to 75-80° C. to dissolve all particles, thereby achieving a solution. The solution was then cooled and seeded with (2S)-2-ethoxy-3-(4-methoxyphenyl) propanoic acid (S)-(−)-1-(1-naphthyl) ethylamine salt. The desired diastereomeric salt was collected by filtration. The crystals were washed with i-PrOAc.
  • The (2S)-2-ethoxy-3-(4-methoxyphenyl) propanoic acid (S)-(−)-1-(1-naphthyl) ethylamine salt obtained (67 g, 169 mmol, 1.0 eq.) was dissolved by heating to 75-80° C. in isopropylacetate (1340 ml. 20 vol.). The product obtained was collected by filtration, washed with isopropylacetate and dried under vacuum, at 40° C., to a constant weight.
  • The overall yield over the two crystallisation steps was 74% of the theoretical value. The chemical purity was >99%. The enantiomeric excess (e.e.) was 97.8%.
  • f) Preparation of (2S)-ethoxy-3-(4-hydroxyphenyl) propanoic acid
  • (2S)-2-ethoxy-3-(4-methoxyphenyl) propanoic acid (S)-(−)-1-(1-naphthyl) ethylamine salt (100g, 253 mmol, 1.0 eq.) was suspended in toluene. The mixture was then treated with NaOH (11.1 g, 278 mmol, 1.1 eq.) in water (280 ml, 5 vol.). The upper toluene layer containing the chiral amine was separated. The lower aq. layer was washed with two more portions of toluene (280 ml, 5 vol.). The lower aq. layer was acidified to pH=1 with aq. 37% HCl (30 g, 304 mmol, 1.2 eq.). The water solution containing (S)-2-ethoxy-3-(4-methoxyphenyl) propanoic acid was extracted with two portions of EtOAc (280 ml. 5 vol.). The combined EtOAc extract was washed with one portion of water (280 ml, 5 vol.). The solvent was replaced with NMP under reduced pressure. NaOH (beads) (45.5 g, 1.14 mol. 4.5 eq.) and octanethiol (129 g, 154 ml, 884 mmol. 3.5 eq.) were charged to the solution of (S)-2-ethoxy-3-(4-methoxyphenyl) propanoic acid (approximately 56.6 g, 253 mmol. 1.0 eq.) in NMP (680 ml, 12 vol.) under a nitrogen atmosphere. The reaction mixture was heated to 120° C. and kept at II 5-125° C. until the reaction was complete as determined by HPLC.
  • The reaction mixture was cooled to 60° C. and then quenched with water. The pH was then adjusted to 2-3 with conc. HCl. The temperature was maintained at 60-70° C. Two layers were formed, the upper layer of which containing mainly octanethiol and the corresponding methyl ether (formed in the reaction). The layers were separated and the layer containing water and NMP was concentrated to 3-4 volumes under vacuum at 80-100° C. inner temperature.
  • The residue was extracted with a mixture of H2O:EtOAc. The EtOAc solution was subsequently washed 3 times with a 15% NaCl solution. The EtOAc was evaporated and the residue was directly used in the subsequent step or could also be crystallized from toluene to yield a white solid.
  • The yield was 52% using crystallisation 90% using only evaporation. The chemical purity was 99.8%. The enantiomeric excess (e.e.) was 97.8%.
  • g) Preparation of ethyl (2S)-2-ethoxy-3-(4-hydroxyphenyl) propanoate
  • (2S)-2-ethoxy-3-(4-hydroxyphenyl) propanoic acid (874 g, 4.16 mol, 1.0 eq.) was dissolved in EtOAc (1250 ml). To this solution were charged ethanol (3000 ml) and HCl (37°, aq.) (40 ml, 0.48 mol, 0.12 eq.). The solution was heated to boiling (about 72° C.) and water/EtOAc/EtOH (2000 ml) was distilled off. Another portion of EtOH (2000 ml) was charged and another 2000 ml was distilled off. This procedure was repeated once more. At this point approximately 95% conversion was reached. Then EtOH (99.5%, 1000 ml) was added and evaporated off. This was repeated until a conversion of>97.5% was achieved. The solution was then concentrated to a volume of 1700-2000 ml under vacuum and then cooled to 20° C.
  • The EtOAc solution containing ethyl (S)-2-ethoxy-3-(4-hydroxyphenyl) propanoate was then charged slowly (30-40 min) under vigorous stirring to a solution of NaHCO3 (7% w/w, 3500 ml). Crystallisation occured after a few minutes. After charging, the slurry was cooled to 0-5° C. and then stirred at 0-5° C. for at least one hour. The crystals were then filtered off and dried under vacuum.
  • The yield was about 93%. The chemical purity was>99%. The enantiomeric excess (e.e.) was>97.8%.
  • Example 2 Ethyl (2,S)-2-ethoxy-3-(4-hydroxyphenyl) propanoate
  • a) Preparation of ethyl 2-chloro-2-ethoxy ethanoate
  • Ethyl 2,2-diethoxy ethanoate (47.5 kg, 263 mol) was treated for 20 h at 60° C. with iodine (0.1 kg) and acetylchloride (21.9 kg, 279 mol, addition time 2 h). The resulting low boiling reaction by-products were distilled off at 40° C./170 mbar resulting in a dark-colored liquid (50 kg, GLC: 89% area, 100 % yield (content corrected).
  • b) Preparation of (1,2-Diethoxy-2-oxoethyl)(triphenyl)phosphonium chloride
  • Ethyl 2-chloro-2-ethoxy ethanoate (50 kg, 268 mol) was added over 70 min at 20-30 ° C. to a solution of triphenylphosphine (71.6 kg, 261.8 mol) dissolved in CH2Cl2 (102 L). For 13 h the reaction was kept at 20° C. CH2Cl2 was then distilled off and TBME (230 L) was added. Upon seeding the material crystallized in big clusters that could not be removed from the reactor. The liquid parts were decanted off. The material was then dried in the reactor by distilling off remaining TBME (jacket temperature of 40° C. and full vacuum). From an aliquot of the original suspension the yield was calculated to be 100% (128 kg, GLC: 92% area).
  • c) Preparation of ethyl 3-[4-(benzyloxy)phenyl]-2-ethoxy-2,-propenoate
  • The crystals of (1,2-diethoxy-2-oxoethyl)(triphenyl)phosphonium chloride in the reactor were dissolved in CH2Cl2 (290 L) followed by the addition of 4-benzyloxybenzaldehyde (44.2 kg, 208 mol, yield is based on this chemical). To this solution tetramethylguanidine (25.4 kg, 220 mol) was added in 1 hour. The solution was then stirred for 20 hours at 20 ° C. CH2Cl2 (200 L) was distilled off and at an Ti of 30° C. replaced with TBME (280 l). The crystals of TPPO formed were filtered off at 20° C. and the mother-liquor was concentrated until a new precipitate was formed. The TPPO was filtered off again and the mother-liquor was concentrated until no more solvents distilled. 2-Propanol (260 L) and seeding crystals (ethyl 3-[4-(benzyloxy)phenyl]-2-ethoxy-2-propenoate) (50 g) were added before cooling to 0° C. The resulting suspension was filtered and the isolated material dried at 40° C./160 mbar. The overall yield was 44.5 kg, 65% (GLC: 99% area).
  • d) Preparation of ethyl 3-[4-(benzyloxy)phenyl]-2-ethoxy-2-propanoate
  • Ethyl 3-[4-(benzyloxy)phenyl]-2-ethoxy-2-propenoate was converted to ethyl 3-[4-(benzyloxy)phenyl]-2-ethoxy-2-propanoate in two identically sized trials. Ethyl 3-[4-(benzyloxy)phenyl]-2-ethoxy-2-propenoate (16 kg, 48.5 mol) was dissolved in EtOAc (80 L) and Pd/C 10% (0.79 kg) suspended in EtOAc (2.5 L) was added. The vessel was inertised and filled-with H2. The hydrogenation was initiated by starting the stirrer and lasted 26 hours. The catalyst was filtered off (glass filter/Cellite (2.5 kg)). The filtrates of both trials were combined and washed with 1 M NaOH (60 L) and saturated NaCt solution (20 L). The clear organic phase was concentrated in vacuo/50° C. to yield 30.6 kg, 91% ethyl 3-[4-(benzyloxy)phenyl]-2-ethoxy-2-propanoate (GLC 94.4% area).
  • e) Preparation of 3-[4-(benzyloxy)phenyl]-2-ethoxypropanoic acid
  • Ethyl 3-[4-(benzyloxy)phenyl]-2-ethoxy-2-propanoate (30.6 kg, 87.9 mol) was dissolved in EtOH (205 L). NaOH 30% (15.6 kg, 114 mol) was added in 12 min. The clear solution was stirred for 9 h at 20° C. and 3 hours at 0C. Water (91 L) was added and EtOH distilled off (195 L, jacket temperature 40° C./110 mbar). TBME (122 L) was added and the emulsion cooled to 0° C. To the well stirred emulsion, H2SO4 (46 L) was added in 50 minutes. The layers were separated and the aqueous layer extracted with TBME (122 L). The combined organic layers were washed with saturated NaCt solution (62 L) and concentrated in vacuo/45° C. to yield 30.6 kg, 100% (GLC 89 % area).
  • f) Preparation of 3-[4-(benzyloxy)phenyl]-2-ethoxy-N-[(IR)-2-hydroxy-1-phenylethyl]propanamide
  • 3-[4-(Benzyloxy)phenyl]-2-ethoxypropanoic acid (30.6 kg, 88 mol) and DMAP (12.9 kg) were dissolved in CH2Cl2(192 L) and cooled to 0° C. To the clear solution EDC×HCl (20.2 kg) was added in 10 minutes. In 18 minutes a solution of (2R)-2-amino-2-phenyl-1-ethanol (14.5 kg, 105.6 mol) in CH2Cl2(60 L) was added, keeping the temperature below 2° C. The reaction mixture was kept at 0° C. for 2 hours and then heated to reflux for ca. 3 hours. The solvent was then distilled off (110 L). EtOAc (110 L) was added and the temperature lowered to 10° C. Over 30 min 1M H2SO4 (110 L, 110 mol) was added, the phases separated and the organic phase extracted with H2SO4 (110 L, 110 mol). To the combined organic phases, 110 L EtOAc and 1 M NaOH (110 L, 110 mol) were added at 10° C. (pH 10). The phases were separated and the organic phase washed with saturated NaCl solution.
  • g) Preparation of (2S)-3-[4-(benzyloxy)phenyl]-2-ethoxy-N-[(1R)-2-hydroxy-1-phenylethyl]propanamide
  • The EtOAc was distilled off (460 L) to yield a white suspension that was filtered, washed six times with EtOAc/heptane 1:1 (totally 15 L). The filtercake was set aside ((R) isomer) and the mother-liquor concentrated to yield 22.15 kg, 54% (GLC 51.7% (2S)-3-[4-(benzyloxy)phenyl]-2-ethoxy-N-[(IR)-(2-hydroxy-1-phenylethyl]propanamide, 21.8% (2R)-3-[4-(benzyloxy)phenyl]-2-ethoxy-N-[(1R)-2-hydroxy-1-phenylethyl]propanamide).
  • The crude enriched material (14.4 kg) was chromatographed in two batches over silica gel(totally 80 kg) using MeOH/CH2Cl2 1:99(800 L) as mobile phase. A total of 4.4 kg, 51% (93% chemical purity, pure (2S)-3-[4-(benzyloxy)phenyl]-2-ethoxy-N-[(IR)-(2-hydroxy-1-phenylethyl]propanamide enantiomer) was obtained.
  • h) Preparation of (2S)-3-[4-(benzyloxy)phenyl]-2-ethoxypropanoic acid
  • (2S)-3 -[4-(benzyloxy)phenyl ]-2-ethoxy-N-[(1R)-2-hydroxy-1-phenylethyl]propanamide (4.3 kg, 10.2 mol) were dissolved in dioxane (30 L) and diluted with deionized water (35 L). To this opaque reaction mixture, H2SO4 (19.2 kg, 192 mol) was added. The reaction temperature was raised to 80 ° C. and kept at 80 ° C. for 15 hours. The reaction mixture was extracted twice with TBME (64 L, 70 L) at room temperature. The combined organic phases were extracted twice with 1 M NaOH (2×20 L, 2×20 mol). The aqueous phases were acidified with H2SO4 (24 L, 24 mol.), extracted with TBME (40 L) and the organic phases dried with saturated NaCl solution. The solution was concentrated to yield 64 L concentrate which contained 2.9 kg, 100% (GLC 68% area (2S)-3-[4-(benzyloxy)phenyl]-2-ethoxypropanoic acid and 28% area (2S)-2-ethoxy-(4-hydroxyphenyl)propanoic acid).
  • i) Preparation of (2S)-2-ethoxy-(4-hydroxyphenyl)propanoic acid
  • To the TBME solution of (2S)-3-[4-(benzyloxy)phenyl]-2-ethoxypropanoic acid, 10% Pd/C (totally 204 g) was added and 0.2 bar hydrogen pressure applied. The hydrogenation lasted 2 hours. The catalyst was filtered off and the solution concentrated (50° C./12 mbar final pressure). Since this crude oil still contained 12% area toluene (by GLC) the residual oil was stripped 5 times with EtOH (5×1 L) until no more toluene was detected in the crude material. 2.2 kg, 92% (GLC: 96% area) of slowly crystallizing oil was obtained.
  • j) Preparation of ethyl (2S)-2-ethoxy-(4-hydroxyphenyl)propanoate
  • Gaseous HCl (2.95 kg) was absorbed into EtOH (10 L) at 0°-4° C. (titrated final content: 24.7% w/v). The temperature rose towards the end to 17° C. at which (2S)-2-ethoxy-(4-hydroxyphenyl)propanoic acid (2.08 kg, 9.9 mol) was added. The temperature was increased to 80° C. and thionyl chloride (1.97 kg, 14.8 mol) was added carefully over 1 hour. The clear solution was kept at reflux for 2 hours and then stirred at 20° C. for 10 h. The solution was then concentrated in vacuo/40° C. to yield 1.98 kg crude ethyl (2S)-2-ethoxy-3-(4-hvdroxyphenyl)propanoate (slowly crystallizing oil). The crude material was dissolved in EtOAc (10 L) and heptane (31 L) and filtered through silica gel (4.0 kg). The silica was washed with EtOAc/heptane=1:3 (12 L) and the filtrate concentrated (45° C./30 mbar) to yield 1.8 kg crystallizing oil. To this EtOAc (1.2 L) and heptane (3.6 L) was added heated to 40 ° C. to obtain a clear solution and slowly cooled to 20 ° C. Occasionally while cooling down seeding crystals (ethyl (2S)-2-ethoxy-3-(4-hydroxyphenyl)propanoate) (pure enantiomer) were added. After 2 hours at 0-2° C. the crystals were filtered off, washed with EtOAc/heptane=1:3 (2.0 L) in 3 portions (0° C.), EtOAc/heptane=1:7 (2.0 L) in 4 portions (0° C.) and heptane (1.6 L). The off-white crystals were dried on a rotary evaporator (40° C./15 mbar, constant weight) to yield 1.09 kg, 48% (GLC: 98.4% area., ee-HPLC 98.7% area).
  • Example 3 Ethyl (2S)-2-ethoxy-(4-hydroxyphenyl)propanoate
  • f) Preparation of 3-[4-(benzyloxy)phenyl]-2-ethoxy-N-[(IS)-(2-hydroxy-1-phenylethyl]propanamide
  • 3-[4-(benzyloxy)phenyl]-2-7ethoxy-N-[(1S)-(2-hydroxy-1-phenylethyl]propanamide was prepared according to step a) to f) in Example 2, using (2S)-2-amino-2-phenyl-1-ethanol.
  • g) Preparation of (2S)-3-[4-(benzyloxy)phenyl]-2-ethoxypropanoic acid
  • The diastereomeric mixture (21.6 kg, 51.6 mol, (2)-3-[4-(benzyloxy)phenyl]-2-ethoxy-N-[(1S)-(2-hydroxy-1-phenylethyl]propanamide/(2R)-3 -[4-(benzyloxy)phenyl]-2-ethoxy-N-[(1S)-(2-hydroxy-1-phenylethyl]propanamide) was suspended in ethyl acetate (113 L) and heated to reflux for 30 min. The solution was slowly (1 h) cooled to 36-40° C. and heptane (113 L) was added under vigorous stirring over 2 h. The mixture was cooled to 15° C. over 4 h.
  • The material was filtered off and washed with a mixture of ethyl acetate and heptane (1:1; 113 L), to yield 5.36 kg of a white solid (HPLC: 97.2% area (2S)-3-[4-(benzyloxy)phenyl]-2-ethoxy-N-[(1S)-(2-hydroxy-1-phenylethyl]propanamide; 2.8% area (2R)-3-[4-(benzyloxy)phenyl]-2-ethoxy-N-[(1S)-(2-hydroxy-1-phenylethyl]propanamide).
  • h) Preparation of (2S)-3-[4-(benzyloxy)phenyl]-2-ethoxypropanoic acid
  • To the reactor was charged deionized water (35.7 L), via the dropping funnel conc. H2SO4 (210 L; 178.97 mol) was added under cooling (the inner temperature was maintained below 10° C.). The solution was transferred to a dropping funnel and the reactor was charged with 1.2-Dimethoxyethane (49.5 L) and (2S)-3-[4-(benzyloxy)phenyl]-2-ethoxv-N-[(1S)-(2-hydroxy-1-phenylethyl]propanamide (5.363 kg; 12.78 mol; enantiomeric purity: HPLC: 96.5% (2S)-3-[4-(benzyloxy)phenyl]-2-ethoxy-N-[(1S)-(2-hydroxy-1-phenylethyl]-propanamide; 3.5 % (2R)-3-[4-(benzyloxy)phenyl]-2-ethoxy-N-[(l S)-(2-hydroxy-1-phenylethyl]propanamide).
  • To the white suspension the H2SO4 solution was added over 1 h (inner temperature 20° C.). The reaction mixture was heated to 80° C. packet temperature: 90° C.) for 15 h. The reaction mixture was cooled to 20° C., TBME (85 L) was added, the mixture was stirred for 20 min and the phases were separated. The aqueous layer was extracted with TBME (84 L). The organic layers were combined and extracted three times with 1 M NaOH (23 L, 23 L. 15 L). The aqueous layers were combined and 1 M H2SO4 was added until pH 1 was achieved (46.5 L were necessary).
  • The aqueous phase was extracted with TBME (80 L). After drying with Na2SO4 (3.37 kg), the solvent was removed under reduced pressure to obtain 4.087 kg of (2S)-3-[4-(benzyloxy)phenyl]-2-ethoxypropanoic acid (enantiomeric purity: HPLC: 96.6% area (2S)-3-[4-(benzyloxy)phenyl]-2-ethoxypropanoic acid).
  • i) Preparation of ethyl (2S)-2-ethoxy-(4-hydroxyphenyl)propanoate
  • The reactor was charged with ethanol (12 L), HCl gas was bubbled through for 7 h. The inner temperature was kept below 10° C.—intensive cooling was necessary. By titration, the content of HCl was determined to be 32.9%. 5 L of the ethanolic HCl were removed, to the residual amount (ca. 10 L) (2-)-3-[4-(benzyloxy)phenyl]-2-ethoxypropanoic acid (4.08 kg, 12.78 mol, calculated on the assumption of 100% yield in the former step h) was added. The suspension was slowly (over I h) warmed up to 20° C. To the resulting solution, thionylchloride (1.85 L, 25.56 mol, 2 equiv.) was added over 30 min—gas was developed heavily. The reaction mixture was slowly heated (jacket temperature: 65° C.). At 35° C. inner temperature the development of gas was so vigorous, that the washer was overburdened. The heating was stopped and the inner temperature was kept at 35° C. for 15 min. Then heating was continued and the reaction mixture was kept under reflux for 2h 30 min. Since conversion was not complete (GC: 46.6% of (2S)-ethoxy-3-(4-hydroxyphenyl) propanoic acid), additional ethanolic HCl (5 L) and additional thionylchloride (1 L, 13.81 mol) was added and heating was continued for 12 h. Still conversion was not complete (GC: 5.3% of (2S).ethoxy-3-(4-hydroxyphenyl) propanoic acid) and HCl-gas was bubbled through the reaction solution at 0-5° C. for 2 h. Then heating to reflux was continued for 2 h 30 min. Nearly complete conversion was achieved (GC: 1.1% of (2S)-ethoxy-3-(4-hydroxyphenyl) propanoic acid). The solvent was removed by distillation under reduced pressure (jacket temperature: 40-50° C.; 250-40 mbar).
  • The remaining oil (3.778 kg, GC: 70.6% of ethyl (2S)-2-ethoxy-(4-hydroxyphenyl)-propanoate; chiral purity: 96.7% of ethyl (2S)-2-ethoxy-(4-hydroxyphenyl)propanoate) was dissolved-in ethyl acetate (11 L). The solution was washed with NaHCO3 (10.5 L). The aqueous phase was re-extracted twice with ethyl acetate (2×7 L). The organic layers were combined, dried with Na2SO4 (1.276 kg) and the solvent was removed in vacuum (jacket temperature: 40° C.; 150-50 mbar) to yield 3.76 kg of a brown oil.
  • The crude product was dissolved in ethyl acetate (3.5 L), under vigorous stirring heptane (7 L) was added over 20 min at 20-23° C. (inner temperature). The solution was slowly (over 1 h 35 min) cooled to 0° C. No precipitation was observed and the solution was seeded with 1.6 g of ethyl (2S)-2-ethoxy-(4-hydroxyphenyl)propanoate and cooled to −5° C. over 2 h. The suspension was stirred for 22 h at −5° C. The solid was filtered off and washed with heptane (6 L). After drying (24 h, jacket temperature: 40° C.) 1.578 kg of a beige solid was obtained (GC: 99.5% area; HPLC: chiral purity: 100% ). Yield: 52% (calculated on (2S)-3-[4-(benzyloxy)phenyl]-2-ethoxy-N-[(1S)-(2-hydroxy-1-phenylethyl]propanamide.
  • The mother liquor was reduced (6 L of solvent were distilled off). At 15° C. ethyl acetate (0.5 L) was added and the cloudy solution was cooled to 2° C. and stirring was continued for 15 h. The suspension was filtered off and washed with heptane (4 L). The brown solid (wet, 295.2g) was re-crystallized from ethyl acetate (300 mL) and heptane (900 mL) to yield after drying 155.8 g of a beige solid (GC purity: 97.7% area.; chiral HPLC e.e.: 100%).
  • 1055.6 g of ethyl (2S)-2-ethoxy-(4-hydroxyphenyl)propanoate were suspended in ethyl acetate (685 mL) and in heptane (2055 mL). At 38° C. inner temperature a clear solution was achieved. The solution was-cooled slowly (1 h 20 min) to 27° C. inner temperature. The solution was seeded with 1 g of ethyl (2S)-2-ethoxy-(4-hydroxyphenyl)propanoate. Cooling was continued to 0° C. within 1 h 30 min. Precipitation started at 15° C. The suspension was filtered off and washed with heptane/ethyl acetate 7:1 (1L). After drying,, 783.4g (GC: 98.7%) of a beige powder were obtained.
  • Abbreviations
    • DMAP=n,n-dimethylaminopyridine
    • DMF=dimethyl formamide
    • EDC=1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride
    • e.e.=enantiomeric excess
    • Et=ethyl
    • EtOac=ethyl acetate
    • GLC=gas-liquid chromatography
    • HPLC=high-pressure liquid chromatography
    • i-PrOAc=isopropyl acetate
    • NMP=n-methyl-2-pyrrolidinone
    • Ph=phenyl
    • TBME=tert-butyl methyl ether
    • THF=tetrahydrofuran
    • TPPO=triphenyl phosphine oxide

Claims (10)

1-21. (canceled)
22. A process for the preparation of a compound of formula VIII
Figure US20060069283A1-20060330-C00011
wherein Q is a protecting group selected from acetyl and C1-3 alkyl, and A is OH, a chiral auxiliary group or the group ORp, wherein Rp is a protecting group, and one or more of the hydrogen atoms of the phenyl group are optionally substituted by the equivalent number of halogen atoms, comprising reducing a compound according to formula VI
Figure US20060069283A1-20060330-C00012
wherein Q is a protecting group or H, and A is OH, a chiral auxiliary group or the group ORp, wherein Rp is a protecting group, and one or more of the hydrogen atoms of the phenyl group are optionally substituted by the equivalent number of halogen atoms, by hydrogenation in the presence of a catalyst.
23. The process according to claim 22 in which the catalyst is a chiral catalyst.
24. The process according to claim 22 in which Q is methyl.
25. The process according to claim 23 in which Q is methyl.
26. The process according to any one of claims 22-25 in which Rp is a protecting group selected from the group consisting of H, benzyl and C1-3 alkyl.
27. The process according to claim 1 in which A is a chiral auxiliary group.
28. The process according to claim 27 in which the chiral auxiliary group is chosen from the group consisting of terpenes and oxazolidinones.
29. The process according to claim 27 or 28 in which the catalyst is palladium on carbon.
30. The process according to any one of claims 22-25, wherein the one or more halogen atoms of formula VI are selected from the group consisting of chlorine and bromine and any combination thereof.
US11/282,247 1999-12-03 2005-11-18 New process Abandoned US20060069283A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/282,247 US20060069283A1 (en) 1999-12-03 2005-11-18 New process

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE9904415-8 1999-12-03
SE9904415A SE9904415D0 (en) 1999-12-03 1999-12-03 New process
PCT/SE2000/002382 WO2001040159A1 (en) 1999-12-03 2000-11-29 New process
US10/148,818 US7002037B2 (en) 1999-12-03 2000-11-29 Process for the preparation on enantiomerically enriched compounds
US11/282,247 US20060069283A1 (en) 1999-12-03 2005-11-18 New process

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US10/148,818 Continuation US7002037B2 (en) 1999-12-03 2000-11-29 Process for the preparation on enantiomerically enriched compounds
PCT/SE2000/002382 Continuation WO2001040159A1 (en) 1999-12-03 2000-11-29 New process

Publications (1)

Publication Number Publication Date
US20060069283A1 true US20060069283A1 (en) 2006-03-30

Family

ID=20417980

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/148,818 Expired - Fee Related US7002037B2 (en) 1999-12-03 2000-11-29 Process for the preparation on enantiomerically enriched compounds
US11/282,247 Abandoned US20060069283A1 (en) 1999-12-03 2005-11-18 New process

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/148,818 Expired - Fee Related US7002037B2 (en) 1999-12-03 2000-11-29 Process for the preparation on enantiomerically enriched compounds

Country Status (20)

Country Link
US (2) US7002037B2 (en)
EP (1) EP1237838B1 (en)
JP (1) JP2003515578A (en)
KR (1) KR100794091B1 (en)
CN (1) CN1213016C (en)
AT (1) ATE264287T1 (en)
AU (1) AU765938B2 (en)
BR (1) BR0016136A (en)
CA (1) CA2392032C (en)
DE (1) DE60009953T2 (en)
DK (1) DK1237838T3 (en)
ES (1) ES2218258T3 (en)
IL (2) IL149576A0 (en)
MX (1) MXPA02005321A (en)
NO (1) NO20022604L (en)
PT (1) PT1237838E (en)
SE (1) SE9904415D0 (en)
TR (1) TR200401717T4 (en)
WO (1) WO2001040159A1 (en)
ZA (1) ZA200203705B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU752059B2 (en) 1997-10-27 2002-09-05 Dr. Reddy's Laboratories Limited Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
MXPA00004036A (en) 1997-10-27 2006-05-24 Reddys Lab Ltd Dr Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them.
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
EP1124807A1 (en) 1997-10-27 2001-08-22 Dr. Reddy's Research Foundation Novel heterocyclic compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
JP2002528535A (en) 1998-10-29 2002-09-03 ドクター・レディーズ・リサーチ・ファウンデーション An improved method for producing new antidiabetic agents
US6531596B1 (en) 1998-10-29 2003-03-11 Dr. Reddy's Laboratories Ltd. Process for the preparation of new antidiabetic agents
SE9904415D0 (en) * 1999-12-03 1999-12-03 Astra Ab New process
US6897199B2 (en) 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US20070142472A1 (en) * 2003-11-27 2007-06-21 Tohru Yokozawa Process for producing optically active 3-(4-hydroxyphenyl)proprionic acids
DE102004035034A1 (en) * 2004-07-20 2006-02-16 Degussa Ag Resolution of p-hydroxyphenyl-2-alkoxy-propionic acids
ITMI20061297A1 (en) 2006-07-04 2008-01-05 Laboratorio Chimico Int Spa PROCEDURE FOR THE PREPARATION OF ACID (R) - (-) - 3- (CARBAMYLMETHYL) -5-METHYLESANOIC AND PREGABALIN AND INTERMEDIATE OF SYNTHESIS
DK2125711T3 (en) 2007-03-08 2014-02-17 Albireo Ab 3-Phenylpropionic AND THEIR USE IN TREATMENT OF Inflammatory Bowel Disease
US8163464B2 (en) * 2008-08-25 2012-04-24 Du Pont Electronic Polymers L.P. Propanoates and processes for preparing the same
CN101838195B (en) * 2009-03-17 2014-08-13 天士力制药集团股份有限公司 Chemical resolution preparation method for optical pure Beta-3, 4-dyhydroxyophenyl lactic acid
CN104447294A (en) * 2014-11-24 2015-03-25 苏州乔纳森新材料科技有限公司 Chiral resolution method of 3-cyclohexene-1-formic acid

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232945A (en) * 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US5306725A (en) * 1989-03-01 1994-04-26 Katayama Chemical Inc. Stabilized isothiazolone liquid formulation
US6048883A (en) * 1992-07-03 2000-04-11 Smithkline Beecham P.L.C. Heterocyclic compounds as pharmaceutical
US6054453A (en) * 1997-10-27 2000-04-25 Redd's Research Foundation Tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them
US6258850B1 (en) * 1998-06-04 2001-07-10 Astrazeneca Ab 3-aryl-2-hydroxypropionic acid derivative (I)
US6362360B1 (en) * 1998-06-04 2002-03-26 Astrazeneca Ab 3-aryl-2-hydroxypropionic acid derivative III
US6630600B1 (en) * 1998-06-04 2003-10-07 Astrazeneca Ab 3-aryl propionic acid derivatives and analogs
US7002037B2 (en) * 1999-12-03 2006-02-21 Astrazeneca Ab Process for the preparation on enantiomerically enriched compounds

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5306725A (en) * 1989-03-01 1994-04-26 Katayama Chemical Inc. Stabilized isothiazolone liquid formulation
US6048883A (en) * 1992-07-03 2000-04-11 Smithkline Beecham P.L.C. Heterocyclic compounds as pharmaceutical
US5232945A (en) * 1992-07-20 1993-08-03 Pfizer Inc. 3-aryl-2-hydroxypropionic acid derivatives and analogs as antihypertensives
US6054453A (en) * 1997-10-27 2000-04-25 Redd's Research Foundation Tricyclic compounds and their use in medicine process for their preparation and pharmaceutical compositions containing them
US6258850B1 (en) * 1998-06-04 2001-07-10 Astrazeneca Ab 3-aryl-2-hydroxypropionic acid derivative (I)
US6362360B1 (en) * 1998-06-04 2002-03-26 Astrazeneca Ab 3-aryl-2-hydroxypropionic acid derivative III
US6630600B1 (en) * 1998-06-04 2003-10-07 Astrazeneca Ab 3-aryl propionic acid derivatives and analogs
US6660879B2 (en) * 1998-06-04 2003-12-09 Astrazeneca Ab 3-aryl-2-hydroxypropionic acid derivative I
US7002037B2 (en) * 1999-12-03 2006-02-21 Astrazeneca Ab Process for the preparation on enantiomerically enriched compounds

Also Published As

Publication number Publication date
ATE264287T1 (en) 2004-04-15
SE9904415D0 (en) 1999-12-03
EP1237838B1 (en) 2004-04-14
DK1237838T3 (en) 2004-07-12
PT1237838E (en) 2004-08-31
DE60009953T2 (en) 2005-03-31
TR200401717T4 (en) 2004-09-21
BR0016136A (en) 2002-08-20
AU2034901A (en) 2001-06-12
AU765938B2 (en) 2003-10-02
KR100794091B1 (en) 2008-01-10
CA2392032C (en) 2008-10-28
CA2392032A1 (en) 2001-06-07
IL149576A (en) 2007-09-20
US7002037B2 (en) 2006-02-21
ZA200203705B (en) 2003-10-29
JP2003515578A (en) 2003-05-07
IL149576A0 (en) 2002-11-10
US20030139474A1 (en) 2003-07-24
DE60009953D1 (en) 2004-05-19
CN1433393A (en) 2003-07-30
MXPA02005321A (en) 2002-12-06
CN1213016C (en) 2005-08-03
WO2001040159A1 (en) 2001-06-07
NO20022604D0 (en) 2002-05-31
ES2218258T3 (en) 2004-11-16
KR20020058071A (en) 2002-07-12
NO20022604L (en) 2002-07-11
EP1237838A1 (en) 2002-09-11

Similar Documents

Publication Publication Date Title
US20060069283A1 (en) New process
US8563775B2 (en) Process for the preparation of (R)-(−)-3-(carbamoylmethyl)-5-methylhexanoic acid and of pregabalin and synthesis intermediates
US8575393B2 (en) Process for the preparation of cinacalcet and salts thereof, and intermediates for use in the process
CA2623355C (en) Resolution of .alpha.-(phenoxy) phenylacetic acid derivatives with naphthyl-alkylamines
US20060247470A1 (en) Process for producing optically active carboxylic acid substituted in 2-position
WO2012101649A1 (en) A novel stereospecific synthesis of (-) (2s,3s)-1-dimethylamino-3-(3-methoxyphenyl)-2-methyl pentan-3-ol
US7829702B2 (en) Racemic separation of 2,6-trans-dimethymorpholine
KR101465025B1 (en) The stereoselective manufacturing method of loxoprofen(2s, 1&#39;r, 2&#39;r) trans-alcohol
WO2004005241A1 (en) Process for producing optically active amide
JPH04308550A (en) Method of stereoselectively converting diol into alcohol
JP3677786B2 (en) Method for producing aryloxypropionic acid
US5166417A (en) Process for resolution of racemates of 2,2-dimethylcyclopropanecarboxylic acid
JP3845884B2 (en) Process for producing N- [1- (2,4-dichlorophenyl) ethyl] -2-cyano-3,3-dimethylbutanamide
JPH0374384A (en) Optical resolution of 3r-(3-carboxybenzyl)-6- (5-fluoro-2-benzothiazolyl)methoxy-4r-chromanol
JPH04230235A (en) Process for optically resolving racemic modification of 2,2-dimethylcyclopropanecarboxylic acid
JPH09151159A (en) Racemization of optically active carboxylic acid
US20060194980A1 (en) Process for the preparation of optically pure isomers of 2-(4-hydroxy phenoxy)-2-methyl-butyric acid methyl ester
JPH0688948B2 (en) Method for optical resolution of 2-phenylpropionic acid esters and method for producing optically active 2-phenylpropionic acid
JP2004059491A (en) Optically active carboxylic acids

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION